P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma

• Liudmila Fedorova,
• Kirill Lepik,
• Natalia Mikhailova,
• Elena Kondakova,
• Yaroslava Komarova,
• Polina Kotselyabina,
• Evgenia Borzenkova,
• Vadim Baykov,
• Ivan Moiseev,
• Alexander Kulagin

Affiliations

Liudmila Fedorova

1 RM Gorbacheva Research Institute, Pavlov University

Kirill Lepik

1 RM Gorbacheva Research Institute, Pavlov University

Natalia Mikhailova

1 RM Gorbacheva Research Institute, Pavlov University

Elena Kondakova

1 RM Gorbacheva Research Institute, Pavlov University

Yaroslava Komarova

1 RM Gorbacheva Research Institute, Pavlov University

Polina Kotselyabina

1 RM Gorbacheva Research Institute, Pavlov University

Evgenia Borzenkova

1 RM Gorbacheva Research Institute, Pavlov University

Vadim Baykov

1 RM Gorbacheva Research Institute, Pavlov University

Ivan Moiseev

1 RM Gorbacheva Research Institute, Pavlov University

Alexander Kulagin

1 RM Gorbacheva Research Institute, Pavlov University